TY - JOUR ID - 90211 TI - Salvage Treatment and Outcomes of Locally Advanced Cervical Cancer after Failed Concurrent Chemoradiation with or without Adjuvant Chemotherapy: Post Hoc Data Analysis from the ACTLACC Trial JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 AU - Asakij, Tussawan AU - Khunnarong, Jakkapan AU - Tangjitgamol, Siriwan AU - Rongsriyam, Kanisa AU - Tharavichitkul, Ekkasit AU - Tovanabutra, Chokaew AU - Paengchit, Kannika AU - Sukhaboon, Jirasak AU - Kridakara, Lieutenant Col. Apiradee AU - Atjimakul, Thiti AU - Pariyawateekul, Piyawan AU - Tanprasert, Prapai AD - Radiation Oncology Section, Lampang Cancer Hospital, Thailand. AD - Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Thailand. AD - Women’s Health Center, MedPark Hospital, Bangkok, Thailand. AD - Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Thailand. AD - Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Chiang Mai University, Thailand. AD - Radiation Oncology Section, Chonburi Cancer Hospital, Thailand. AD - Gynecologic Oncology section, Lampang Cancer Hospital, Thailand. AD - Radiation Oncology Section, Lopburi Cancer Hospital, Thailand. AD - Radiation Oncology Section, Bhumibol Adulyadej Hospital, Thailand. AD - Department of Obstetrics and Gynecology, Prince of Songkla University, Thailand. AD - Obstetrics and Gynecology Section, Bhumibol Adulyadej Hospital, Thailand. AD - Obstetrics and Gynecology Section, Rajburi Hospital, Thailand. Y1 - 2022 PY - 2022 VL - 23 IS - 7 SP - 2263 EP - 2269 KW - Adjuvant chemotherapy KW - Concurrent chemoradiation therapy KW - locally advanced cervical cancer KW - Salvage therapy DO - 10.31557/APJCP.2022.23.7.2263 N2 - Objectives: To evaluate the type of salvage treatment and outcomes of patients with locally advanced cervical cancer who failed treatment with concurrent chemoradiation with or without adjuvant chemotherapy. Methods: This was post hoc analyses of data from the randomized trial which included 259 patients who had FIGO stage IIB-IVA and had either pelvic radiation therapy concurrent with cisplatin followed by observation or paclitaxel plus carboplatin. Data of the patients who failed primary treatment were collected: type of salvage treatments, time to progress after salvage therapy, progression-free (PFS) and overall survivals (OS). Results: After primary treatment, 85 patients had either persistence (36.5%), progression (18.8%), or recurrences (44.7%). The sites of failure were loco/regional in 52.9%, systemic failure in 30.6%, and loco-regional and systemic in 16.5%. Chemotherapy was given in 51.8%, being the sole therapy in 34.1%. Majority were combination agents (31.8%), with paclitaxel/carboplatin as the most common regimen. Radiation to the metastatic sites along with chemotherapy was used in 14.1% whereas palliative radiation therapy or supportive care was used in approximately 10% of each. The median time from the start of salvage treatment to progression was 9.2 months (range 0.2-64.0 months) with median PFS of 11.2 months (95% CI, 7.2-15.3 months). Median overall survival 27.3 months (95% CI, 4.4-69.6 months). Conclusions: Chemotherapy, either alone or with radiation therapy, was the most common salvage treatment in LACC after failure from primary treatment. The time to progress and PFS were less than 1 year with OS of approximately 2 years. UR - https://journal.waocp.org/article_90211.html L1 - https://journal.waocp.org/article_90211_9f235929c77ea2917e7603cfff6b30f0.pdf ER -